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PKC-I~I. Inhibitors of nitric oxide production did not promote sur- 
vival and an inhibitor of PKC-5 caused cell death on both poly- 
L-lysine and FN. PKC-I~I was noted to translocate from the cy- 
tosol to the particulate membrane after plating on poly-L-lysine 
and this translocation was inhibited by the addition of an antiox- 
idant. Time-course analyses implicated endogenous ROS pro- 
duction as a secondary messenger leading to PKC-I~I activation 
and subsequent chondrocyte cell death. Cell survival on poly-L- 
lysine was improved by 50% in the presence of oligomycin which 
suggested the electron transport chain of the mitochondria as a 
candidate for the production ROS. However, cell death on poly- 
L-lysine was not associated with DNA fragmentation or activation 
of caspase activity consistent with necrotic rather than apoptotic 
cell death. Significant ATP depletion was noted in chondrocytes 
on poly-L-lysine suggesting a potential mechanism for a switch 
from apoptosis (which requires energy) to necrosis. 
Conclusion:  These results support a novel mechanism for chon- 
drocyte death when matrix and growth factor signals are lost that 
includes increased ROS production and activation of PKC-I~I. The 
signaling was PKC isoform specific since PKC-5 inhibition re- 
sulted in cell death suggesting it is required for survival signaling 
whereas activation of PKC-I~I promoted chondrocyte cell death. 
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The Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) 
was a randomized double-blind placebo (P)- and celecoxib (CE)- 
controlled trial of 1583 OA patients designed to evaluate the effi- 
cacy of glucosamine (G), chondroitin sulfate (CS), and combina- 
tion (G+CS) in improving osteoarthritis (OA) knee pain. We calcu- 
lated the sample size needed to declare as statistically significant 
the treatment effect sizes observed in GAIT for each active treat- 
ment group compared with placebo, assuming power of 90% and 
two-sided alpha of 5% for each comparison. Sample sizes re- 
quired for 1) the primary outcome measure, which classified pa- 
tients as a treatment responder if they had a 20% reduction in the 
Western Ontario and McMaster University Osteoarthritis Index 
(WOMAC) summed pain subscale at the end of treatment com- 
pared with the baseline measurement, 2) response using the Out- 
come Measures in Rheumatology Clinical Trials -Osteoarthritis 
Research Society International (OMERACT-OARSI) criteria, 3) 
change in WOMAC pain from baseline to end of follow-up, 4) 
change in WOMAC function and 5) change in Health Assessment 
Questionnaire (HAQ) pain. We also assessed the influence of the 
placebo response rate and baseline level of pain on the required 
sample sizes. These results are shown in the table. 
For WOMAC Pain 20% Response and OMERACT-OARSI Re- 
sponse, sample sizes decreased as the placebo response rate 
decreased. Overall, sample sizes were smaller for patients with 
moderate-to-severe knee pain due to OA than for patients with 
mild pain. OMERACT-OARSI Response generally required the 
smallest sample sizes. 
When planning randomized clinical trials of OA treatments for 
knee pain, the OMERACT-OARSI responder criteria will yield 
smaller sample size requirements. In addition, it is important to 
consider the expected level of pain patients may report at study 
entry. 
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Aim of Study: Proteinase-activated receptors (PARs) represent 
a family of seven transmembrane domain G protein coupled re- 
ceptors. They are activated by a proteolytic leavage generating 
a tethered activating ligand at the N-terminus. Four members of 
this family have been identified, and named PAR-l, -2, -3 and -4. 
PAR-2 plays a role in both neurogenic inflammation and hyperal- 
gesia by promoting the release of substance R PAR-2 was also 
recently suggested to be involved in inflammation and to induce 
the synthesis of catabolic and inflammatory factors. Until now, 
little has been reported on the involvement of this factor in hu- 
man osteoarthritic articular tissues. In this study, we investigated 
Abstract A 15- Table 1. Sample Sizes 
CE vs. P G vs. P CS vs. P G+CS vs. P Placebo Response 
WOMAC Pain 20% Response 
All 992 6606 3570 2368 60.1% 
Mild Pain* 1318 27450 4278 68882 61.7% 
Moderate-to-Severe Pain# 458 808 2086 162 54.3% 
OMERACT-OARSI Response 
All 950 7544 2368 1360 56.9% 
Mild Pain* 1496 >100000 3222 7816 59.3% 
Moderate-to-Severe Pain# 332 372 1082 154 48.6% 
Change in WOMAC Pain 
All 2636 49668 >100000 2456 -86.1 
Mild Pain* 5416 5938 97228 41872 -75.6 
Moderate-to-Severe Pain# 492 1380 84296 154 -123.0 
Change in WOMAC Function 
All 1428 > 100000 81016 2262 -227.4 
Mild Pain* 2434 3590 30606 35496 -209.2 
Moderate-to-Severe Pain# 462 504 >100000 200 -291.6 
Change in HAQ Pain 
All 2546 91538 22886 1870 -16.6 
Mild Pain* 6334 8490 > 100000 6334 - 15.0 
Moderate-to-Severe Pain# 448 1320 1222 276 -22.1 
*Mild Pain: Summed WOMAC Pain Score of 125-300mm, #Moderate-to-Severe Pain: Summed WOMAC Pain Score of 301-400mm 
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PAR-2 levels and modulation in human normal and osteoarthritic 
cartilage and synovial membrane as well as its role in the in situ 
synthesis of catabolic factors. The effects of PAR-2 on metallo- 
protease (MMP)-I and cyclooxygenase (COX)-2 production were 
evaluated. 
Methods: PAR-2 levels were determined using immunohis- 
tochemistry. The protein modulation was investigated on os- 
teoarthritic tissue explants treated for 48 hours as follows: for 
cartilage and synovial membrane with a PAR-2 activating peptide 
(400 I~M), IL-11~ (100 pg/ml) or TNFo~ (5 ng/ml); and for cartilage 
with a specific inhibitor of MEK1/2, PD 98059 (10 I~M), p38, SB 
202190 (10 I~M), NF-KB, SN50 (50 I~M), or COX-2, NS-398 (10 
I~M). MMP-1 and COX-2 production were also evaluated following 
stimulation using the PAR-2 activating peptide. 
Results: PAR-2 is produced in both human cartilage and syn- 
ovial membrane; its expression is significantly increased in os- 
teoarthritic tissues compared to normal (p<0.03). PAR-2 produc- 
tion is significantly upregulated by IL-11~, TNFo~, and PAR-2 acti- 
vating peptide in both articular tissues. The PAR-2 activating pep- 
tide also markedly induces MMP-1 and COX-2 production. Inter- 
estingly, only the specific p38 inhibitor, SB 202190, was able to 
down-regulate PAR-2. 
Conclusion: This study documents that PAR-2 is present at 
increased levels in human osteoarthritic artilage and synovial 
membrane, and identifies the major signaling pathway regulating 
its synthesis. We also demonstrated, for the first time, that the 
specific PAR-2 stimulation can activate major pathophysiological 
pathways of the disease such as the synthesis of MMP and COX- 
2. These results suggest PAR-2 as a potential new therapeutic 
target for the treatment of inflammation in osteoarthritis. 
BL. WORMS scores were rescaled to a range of 0-15 to allow 
comparability of odds ratios (OR) for an increase of 1 unit. 
MRI findings were common, with CRT and any bone lesion (BMA, 
CYS or ATR) each in over 50% of N KP knees. Lesion scores were 
highly correlated within (R=0.50-0.77), but not between, compart- 
ments. Higher scores for nearly all lesions in both TFCs were 
associated with KPO (table) and PKP (not shown), while lesions 
in the PFC were weakly or not associated with KPO and PKP. 
Lateral TFC findings, especially bone lesions, were stronger pre- 
dictors of KPO, while predictors of PKP were similar by TFC. SYN 
and LIG had modest associations (OR 1.1 to 1.5) with KPO and 
PKR 
Odds ratios (95% CI) for KPO and PKP 
MRI Medial TFC Lateral TFC PFC 
Univar for KPO (vs NKP) 
OST 1.3 (1.1, 1.5) 1.6 (1.3, 1.9) 1.3 (1.1, 1.5) 
CRT 1.1 (1.0, 1.2) 1.3 (1.1, 1.5) 1.1 (1.0, 1.2) 
BMA 1.4 (0.9, 2.3) 1.8 (1.1, 3.0) 1.2 (1.0, 1.4) 
CYS 1.9 (1.3, 2.9) 2.2 (1.3, 3.9) 1.2 (0.9, 1.6) 
ATR 1.0 (0.7, 1.4) 1.8 (1.3, 2.5) 1.0 (0.8, 1.2) 
MEN 1.2 (1.0, 1.3) 1.4 (1.2, 1.6) 
Multivar for KPO (vs NKP) 
TOTAL 1.2 (0.9, 1.6) 1.7 (1.2, 2.4) 1.1 (0.9, 1.3) 
Multivar for PKP (vs KPR) 
TOTAL 1.3 (1.1, 1.5) 1.4 (1.2, 1.8) 1.1 (1.0, 1.4) 
Despite a high prevalence of MRI findings in knees of elderly sub- 
jects, higher lesion scores in TFCs at baseline predict both the 
onset of KP and the persistence of KP over 4 years follow-up. 
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OA knee pain (KP) varies over time and it is not known whether 
knee abnormalities assessed by MRI predict longitudinal patterns 
of KP. We used 5 annual assessments of KP in elderly subjects 
to identify knees with common patterns of KP occurrence and 
evaluate baseline (BL) MRI predictors of these patterns. 
1028 participants (62% female; 39% Afr-Am) age 71-80 in the 
Health ABC study had BL knee MRI (1.5 T) and KP assessments 
at BL and 4 annual follow-ups (FU). Axial, coronal and sagittal 
(fat suppressed) T2-weighted FSE sequences were scored using 
WORMS for cartilage damage (CRT), osteophytes (OST), bone 
marrow abnormality (BMA), bone cysts (CYS) and bone attrition 
(ATR) in tibiofemoral (TFC) and patellofemoral (PFC) compart- 
ments; meniscal lesions (MEN) in TFCs; ligament damage (LIG) 
and synovial distention (SYN). Scores summing all lesions in a 
compartment were calculated. A positive report of KP at a visit 
was defined as pain on most days of a month in the past year, or 
_> moderate pain in the past 30 days by WOMAC. Of knees with 
both WORMS and KP data, 410 had no KP (NKP) at any visit, 
88 had KP onset (KPO) after BL, 219 had persistent KP (PKP) 
at all visits and 223 had KP that resolved (KPR) after BL. Lo- 
gistic regression with GEE was used to evaluate MRI predictors 
of KPO (vs. NKP) and of PKP (vs. KPR), adjusting for age, sex, 
race, clinic, smoking, NSAID use, BMI, and contralateral KP at 
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Aim of Study: Little is known of pain over time in knee os- 
teoarthritis (OA). We evaluated the change in pain over 6-9 years 
in a meniscectomy population enriched in subjects with early- 
stage or established knee OA. 
Methods: We evaluated 263 patients with no cruciate ligament 
injury with the validated and self-administered Knee injury and 
Osteoarthritis Outcome Score (KOOS) (table 1). The 1st evalua- 
tion was performed 13-22 years after isolated meniscal resection 
and the 2 nd (2004) after 19-32 years (followup rate 70%). The in- 
terval between the assessments was 6-9 years. A change of _> 10 
KOOS points was considered clinically relevant. Standing semi- 
flexed tibiofemoral and skyline patellofemoral radiographs from 
the 1 st assessment were graded according to the OARSI atlas. 
We considered radiographic OA to be present if any of the fol- 
lowing was found in a knee compartment: JSN grade 2 or higher, 
sum of the 2 marginal osteophyte grades _> 2, or grade 1 JSN in 
combination with a grade 1 osteophyte in the same compartment. 
Results: Radiographic OA at the 1 st assessment was present in 
134/263 (51%) index knees. Subjects with radiographic knee OA 
at entry had more knee pain at both the 1 st and 2ndassessment 
(mean -9.1 and -13.6 KOOS points) compared with individuals 
with no radiographic knee OA (p _< 0.005). Subjects with knee 
OA at entry reported increased knee pain (p < 0.001), subjects 
without OA did not (p = 0.06, figure 1 ). There were 16/46 subjects 
with radiographic knee OA that remained pain free compared with 
36/56 of those without radiographic OA (p = 0.11). Of the 6 sub- 
jects with arthroplastic surgery during the observation period, 3 
individuals reported less pain, the other 3 subjects reported sim- 
ilar or worse (lower) scores. The daily use (at 2 nd assessment) of 
